Biocardia, INC Form 4 insider transactions

BioCardia's Chief Financial Officer, David McClung, reported the vesting of restricted stock units and the grant of new stock options as part of his compensation.

BioCardia's Senior Vice President, Edward M. Gillis, received significant equity compensation through RSU vesting and new stock option grants.

BioCardia Director Jim L. Allen was granted 12,000 stock options with an exercise price of $1.37, vesting over one year.

BioCardia, Inc. Director Jay M. Moyes was granted 12,000 stock options with an exercise price of $1.37, vesting in one year.

BioCardia, Inc. Director Bill Facteau was granted 12,000 stock options with an exercise price of $1.37, vesting one year from the grant date.

BioCardia, Inc. Director Simon H. Stertzer was granted 12,000 stock options with an exercise price of $1.37, vesting one year from the grant date.

BioCardia Director Andrew Scott Blank acquired 12,000 stock options with an exercise price of $1.37, vesting one year from the grant date.

BioCardia Director Marvin Slosman was granted 12,000 stock options with an exercise price of $1.37, vesting over one year.

BioCardia Director Simon H. Stertzer acquired 398,400 shares and an equal number of warrants in a public offering, signaling increased confidence.

BioCardia Director Andrew Scott Blank acquired 288,000 shares of common stock and an equal number of warrants at $1.25 per unit, increasing his indirect beneficial ownership.

BioCardia's President and CEO, Peter Altman, acquired 48,000 shares of common stock and an equal number of warrants in a public offering on September 19, 2025.

BioCardia Inc.'s President and CEO, Peter Altman, has reported a planned acquisition of 700 shares of common stock at a weighted average price of $1.83 per share.

BioCardia's President and CEO, Peter Altman, purchased 100 shares of common stock at $1.83 per share, with a reported transaction date in August 2025.

BioCardia's President and CEO, Peter Altman, acquired 400 shares of common stock through a pre-arranged trading plan.

BioCardia's President and CEO, Peter Altman, has filed a Form 4 indicating a future purchase of 1,700 shares of common stock on August 11, 2025, under a Rule 10b5-1 plan.

BioCardia, Inc.'s Chief Financial Officer, David McClung, acquired 4,819 shares of common stock and 4,819 warrants through a private placement on June 30, 2025, increasing his direct beneficial ownership.

BioCardia, Inc. CEO Peter Altman acquired 24,096 shares of common stock and an equal number of warrants through a private placement on June 30, 2025, significantly increasing his direct beneficial ownership.

BioCardia, Inc. Director Simon H. Stertzer acquired 72,289 shares of common stock and an equal number of warrants through a private placement, significantly increasing his beneficial ownership.

BioCardia, Inc. Director and 10% owner Andrew Scott Blank acquired 72,289 shares of common stock and an equal number of warrants through a private placement on June 30, 2025.

BioCardia, Inc. President and CEO Peter Altman reported a pre-planned acquisition of 100 shares of common stock at $2.21 per share, increasing his direct beneficial ownership to 141,766 shares.

BioCardia's President and CEO, Peter Altman, recently purchased additional shares of the company's common stock, increasing his beneficial ownership.

Peter Altman, the President and CEO of BioCardia, Inc., recently purchased additional shares of the company's common stock.

Director Richard M. Krasno acquired 13,123 shares of BioCardia, Inc. common stock and warrants in a private placement on April 23, 2025.

David McClung, CFO of BioCardia, Inc., acquired 13,123 shares of common stock and warrants in a private placement on April 23, 2025.

Director Bill Facteau acquired 13,123 shares of BioCardia, Inc. common stock and warrants in a private placement on April 23, 2025.

Director Andrew Scott Blank acquired shares and warrants of BioCardia, Inc. through a private placement on April 23, 2025.

Director Simon H. Stertzer acquired shares and warrants of BioCardia, Inc. through a private placement on April 23, 2025.

BioCardia's President and CEO, Peter Altman, participated in a private placement, acquiring shares of common stock and warrants.

BioCardia's President and CEO, Peter Altman, purchased 100 shares of common stock at $2.14 per share on April 15, 2025.

BioCardia's CEO, Peter Altman, recently purchased additional shares of the company's common stock, signaling confidence in the firm.